Goldman Sachs Group set a CHF 325 target price on Roche (VTX:ROG) in a report released on Wednesday. The firm currently has a buy rating on the healthcare company’s stock.

Several other brokerages also recently weighed in on ROG. set a CHF 203 price objective on shares of Roche and gave the company a sell rating in a research report on Friday, October 20th. Baader Bank set a CHF 256 price objective on shares of Roche and gave the company a buy rating in a research report on Tuesday, November 21st. Barclays set a CHF 305 price objective on shares of Roche and gave the company a buy rating in a research report on Wednesday, December 27th. Berenberg Bank set a CHF 260 price target on shares of Roche and gave the stock a neutral rating in a research report on Tuesday, October 24th. Finally, DZ Bank set a CHF 270 price target on shares of Roche and gave the stock a buy rating in a research report on Friday, February 2nd. Four analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and an average target price of CHF 257.20.

Shares of Roche (VTX:ROG) opened at CHF 215.95 on Wednesday. The firm has a market cap of $185,900.00 and a PE ratio of 21.51. Roche has a 52-week low of CHF 214.30 and a 52-week high of CHF 273.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://theolympiareport.com/2018/02/11/roche-rog-given-a-chf-325-price-target-by-goldman-sachs-group-analysts.html.

About Roche

Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.

Analyst Recommendations for Roche (VTX:ROG)

Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.